Real-World data shows mepolizumab may keep rare vasculitis in check Long-Term
NCT ID NCT07591753
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study followed 591 adults with eosinophilic granulomatosis with polyangiitis (EGPA) across Europe to see how well mepolizumab 300mg every 4 weeks works over the long term in everyday medical practice. Researchers looked at disease control, lung function, and safety by reviewing medical records. The goal is to understand if this dose helps patients stay well and reduce steroid use without unexpected side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mepolizumab (a biologic drug given as a shot every 4 weeks)
- What this could lead to
- If successful, this could confirm that mepolizumab 300mg/month is a safe and effective long-term treatment to control EGPA and reduce steroid use.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by other factors. It also looks back at existing data, which can be less reliable than a prospective study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS) (EGPA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Florence
Florence, Florence, 50134, Italy